Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Trinity Loveless

Pediatrics Yukon, OK Medical Doctor

NPI 1255537379 CMS profile 826456

812 S Mustang Rd, Yukon, OK 73099

Open in the dashboard

General payments

$2,564

129 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Trinity Loveless of Yukon, OK is reported in the CMS Open Payments database as having received $2,564 across 129 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $447 24
2024 General $712 20
2023 General $306 16
2022 General $411 22
2021 General $262 20
2020 General $265 16
2019 General $161 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Trinity Loveless
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Trinity Loveless were reported at $447. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Trinity Loveless Pediatrics median Middle half National median
2019 $161 $86 $31–$183 $163
2020 $265 $49 $22–$110 $114
2021 $262 $68 $27–$158 $132
2022 $411 $77 $30–$173 $149
2023 $306 $88 $33–$190 $160
2024 $712 $94 $34–$206 $164
2025 $447 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $705 29 payments
  2. Ironshore Pharmaceuticals Inc. $344 16 payments
  3. Pfizer Inc. $298 17 payments
  4. Tris Pharma Inc $184 12 payments
  5. Collegium Pharmaceutical, Inc. $182 10 payments
  6. Sobi, Inc $161 10 payments
  7. Sanofi-Aventis U.S. LLC $160 4 payments
  8. Sanofi Pasteur Inc. $78 5 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $73 4 payments
  10. Merck Sharp & Dohme Corporation $55 4 payments
  11. Other $324 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,564 129 payments
Products named General payments · program years 2019–2025
  1. Qelbree Viloxazine Hydrochloride $443 10 payments
  2. QELBREE Psychology $262 19 payments
  3. JORNAY PM Central Nervous System Stimulant $201 9 payments
  4. Jornay PM Adhd $182 10 payments
  5. SYNAGIS $161 10 payments
  6. TZIELD $160 4 payments
  7. EUCRISA $152 9 payments
  8. JORNAY PM Central Nervous Stimulant ADHD $130 6 payments
  9. PREVNAR 20 $129 7 payments
  10. PENBRAYA $113 6 payments
  11. Other $1,207 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

129 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record